iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Emcure Pharmaceuticals Raises Rs 582.6 Crore from Institutional Investors

3 Jul 2024 , 09:33 AM

Pune-based Emcure Pharmaceuticals has raised ₹582.6 Crore through an anchor book launched on July 2, a day before its issue opening on July 3. The issue will close on July 5.

Marquee Global Investors Participation

Notable global investors such as the Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley acquired shares worth over ₹71 Crore from the anchor book.

Allocation Details

The pharmaceutical company informed exchanges that it finalized the allocation of 57,79,850 equity shares to anchor investors at ₹1,008 per equity share. Several mutual fund houses, including SBI, HDFC, ICICI Prudential, Whiteoak Capital, Aditya Birla Sun Life Trustee, Axis, Kotak, Nippon Life India, Mirae, Franklin India, UTI, Canara Robeco, and Motilal Oswal, also participated in the anchor book.

“Out of the total allocation of 57,79,850 equity shares to anchor investors, 28,15,962 shares (i.e., 48.72% of the total allocation to anchor investors) were allocated to 16 domestic mutual funds through a total of 29 schemes,” Emcure stated in its filing to exchanges.

Additional Institutional Investors

In addition to mutual funds, prominent insurance companies such as HDFC Life Insurance Company, ICICI Prudential Life Insurance Company, SBI Life Insurance Company, Bajaj Allianz Life Insurance Company, and Max Life Insurance Company also invested in Emcure. Other investors included Amundi Funds, Neuberger Berman Emerging Markets Equity Fund, and The Prudential Assurance Company.

IPO Details

Emcure Pharmaceuticals aims to raise ₹1,952.03 Crore through its initial public offering (IPO), which consists of a fresh issuance of shares worth ₹800 Crore and an offer-for-sale (OFS) of 1.14 Crore shares worth ₹1,152.03 Crore by existing shareholders. Prominent shareholders participating in the OFS include promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta.

The price band for the public issue has been set at ₹960-1,008 per share. The company has reserved 1,08,900 equity shares for its employees, who will receive these shares at a discount of ₹90 per share to the final issue price.

Kotak Mahindra Capital Company, Axis Capital, Jefferies India, and JP Morgan India are acting as the book-running lead managers for the issue.

Related Tags

  • Emcure Pharma
  • Emcure Pharma IPO
  • Emcure Pharma IPO anchor book
  • Emcure Pharma IPO details
  • Emcure Pharma IPO news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.